Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Teva UK Ltd and Others v Gilead Sciences Inc (C-121/17)
Consideration of the question referred
46

Teva UK Ltd and Others v Gilead Sciences Inc (C-121/17)

Judgment of 25 Jul 2018law://eu/cjeu/2017/c-121-17/para_46@2026-11-10

46It follows from the above that the subject matter of the protection conferred by an SPC must be restricted to the technical specifications of the invention covered by the basic patent, such as claimed in that patent.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Grand Chamber
Case: C-121/17 · ECLI:EU:C:2018:585
Decided: 25 Jul 2018
Procedure: Preliminary reference · referred by the High Court of Justice (England & Wales), Chancery Division (Patents Court)
Applicants: Teva UK Ltd; Accord Healthcare Ltd and 3 more
Lupin Ltd; Lupin (Europe) Ltd; Generics (UK) Ltd, trading as Mylan
Defendant: Gilead Sciences Inc.
Rapporteur: K. Jürimäe
Advocate General: M. Wathelet
Bench: 13 judges
K. Lenaerts, A. Tizzano, R. Silva de Lapuerta, M. Ilešič, J.L. da Cruz Vilaça, C.G. Fernlund, C. Vajda, J.-C. Bonichot, A. Arabadjiev, C. Toader, M. Safjan, S. Rodin, K. Jürimäe
Language: English
Official: CURIA · EUR-Lex 62017CJ0121

Topics

Intellectual, industrial and commercial property Pharmaceutical and cosmetic products

History · 1 version

25 Jul 2018Reading

Connections

Interprets 1: Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance )
Cited by 2: Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLC v Clonmel Healthcare Limited (C-119/22)3 provisions; Royalty Pharma Collection Trust v Deutsches Patent- und Markenamt (C-650/17)8 provisions
Cites 6: Actavis Group PTC EHF and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KG (C-577/13); Actavis Group PTC EHF and Actavis UK Ltd v Sanofi (C-443/12); Medeva BV v Comptroller General of Patents, Designs and Trade Marks (C-322/10); Eli Lilly and Company Ltd v Human Genome Sciences Inc (C-493/12); Georgetown University and Others v Comptroller General of Patents, Designs and Trade Marks (C-422/10); Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance )